Oncolytic VACVs expressing CTLA-4 inhibitors and GM-CSF elicited robust systemic CD8+ T-cell-dependent anti-tumor immunity and long-lasting anti-tumor immunity by expanding peripheral effector CD8+ T-cells and reducing Tregs and exhausted CD8+ T-cells (94). The gene discussed is CSF2; the disease is neoplasm.